Table 1.
Study population
|
N = 26
Median (IQR) |
|
|---|---|
| Demographic data | |
| Gender female | 17 (65)a |
| Age, years | 65.5 (14.0) |
| BMI, kg/m2 | 25.0 (6.5) |
| Smoking habit | |
| Pack years | 30.4 (22.4) |
| Current smoker | 4 (15)a |
| Medication | |
| LTOT | 3 (12)a |
| SABA/LABA | 24 (92)a |
| Statin | 4 (15)a |
| ACE/AII | 3 (12)a |
| Thiazide | 3 (12)a |
| ASA | 3 (12)a |
| Spirometry | |
| FVC, % of pred | 81.0 (35.3) |
| FEV1, % pred | 40.5 (30.3) |
| FEV1/FVC, ratio | 0.46 (0.21) |
| DLCO1, mmol/min/kPa | 3.92 (2.49) |
| RV/TLC2, ratio | 0.56 (0.20) |
| Clinical data | |
| CAT, score | 18 (7) |
| MMRC, score | 2.0 (1.0) |
| 6-MWD3, meter | 420 (205) |
| BODE index | 2.0 (4.0) |
| Laboratory data | |
| PaO2, kPa | 9.66 (1.98) |
| PaCO2, kPa | 5.07 (.96) |
| SaO2, % | 96.2 (3.3) |
| Alcohol, ppt | 0.81 (0.64) |
IQR inter quartile range, BMI body mass index, LTOT long-term oxygen therapy, SABA/LABA short- and/or long-acting beta-2 receptor agonist, ACE/AII angiotensin converting enzyme and/or angiotensin II antagonist, Thiazide hydrochlorothiazide, ASA acetylic salicylic acid, FVC % of pred forced vital capacity as percent of predicted value, FEV1% of pred forced expiratory volume first second as percent of predicted value, DLCO diffusing capacity of the lung for carbon monoxide, RV residual volume, TLC total lung capacity, CAT COPD assessment test, MMRC modified medical research council questionnaire, 6-MWD 6 min walking distance, BODE BMI/obstruction/dyspnea/exercise capacity, P a O 2 arterial pressure of oxygen, P a CO 2 arterial pressure of carbon dioxide, S a O 2 arterial oxygen saturation,. Alcohol parts per thousand measured by breath analysis immediately prior to sleep
a N (% of study subjects), instead of median (IQR)
1 N = 22, four missing from DLCO because of insufficient vital capacity or because they could not hold their breath for 10 s
2 N = 24, two missing from body plethysmography because of claustrophobia
3 N = 25, one missing from 6-MWD, reason unknown